Home › Peripheral T-Cell Lymphoma › New Jersey
Peripheral T-Cell Lymphoma clinical trials in New Jersey
3 studies for Peripheral T-Cell Lymphoma are looking for participants at sites in New Jersey.
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Hackensack University Medical Center, Hackensack
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06561048A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division, Hackensack
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT07192471To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
- Rutgers Cancer Institute of New Jersey, New Brunswick
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT06072131From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.